Current State and Future Perspective of Molecular Diagnosis of Fine-Needle Aspiration Biopsy of Thyroid Nodules
Современное состояние и перспективы молекулярной диагностики при тонкоигольной аспирационной биопсии узлов щитовидной железы
2011-05-18
SCID: 54.1/ydn9x8a4
Discuss with AI
fine-needle aspiration biopsyindeterminate follicular lesionsmRNA and microRNA expressionsomatic mutation panelthyroid nodule molecular diagnosis
Figures from the paper
Abstract (AI)
CONTEXT: Fine-needle aspiration biopsy (FNAB) is the most sensitive and specific tool for the differential diagnosis of thyroid malignancy. Some limitations of FNAB can be overcome by the molecular analysis of FNAB. This review analyzes the current state and problems of the molecular analysis of FNAB as well as possible goals for increasing the diagnostic rate, especially in the indeterminate/follicular lesion cytological group. EVIDENCE ACQUISITION: Twenty publications were evaluated for the diagnostic material and assay systems used, the type, and the number of mutations screened. Sensitivity, specificity, and false-negative and false-positive rates were calculated for all publications. EVIDENCE SYNTHESIS: Testing for a panel of somatic mutations is most promising to reduce the number of indeterminate FNAB. A mean sensitivity of 63.7% was achieved for indeterminate lesions. However, there is a broad sensitivity range for the investigation of mutations in the indeterminate lesions. Therefore, additional molecular markers should be defined by mRNA and microRNA expression studies and evaluated in FNAB samples of thyroid carcinomas without known somatic mutations, and especially for the many benign nodules in the indeterminate/follicular lesion fine-needle aspiration cytology category. This approach should improve the differential diagnosis of indeterminate/follicular lesion FNAB samples. CONCLUSION: Testing for a panel of somatic mutations has led to an improvement of sensitivity/specificity for indeterminate/follicular proliferation FNAB samples. Further methodological improvements, standardizations, and further molecular markers should soon lead to a broader application of molecular FNAB cytology for the differential diagnosis of thyroid nodules and to a substantial reduction of diagnostic surgeries.
Key Findings
1
Across evaluated studies, somatic mutation testing achieved a mean sensitivity of 63.7% for indeterminate thyroid lesions, with substantial variability between investigations.
2
Additional mRNA and microRNA markers are needed for carcinomas lacking known somatic mutations and for benign nodules classified as indeterminate or follicular lesions.
3
Further methodological improvements and standardization could broaden molecular FNAB application and substantially reduce diagnostic thyroid surgeries.
4
Molecular analysis of thyroid fine-needle aspiration biopsy can overcome some limitations of cytology in diagnosing thyroid malignancy.
5
Panels of somatic mutations are the most promising molecular approach for reducing indeterminate thyroid FNAB diagnoses.
Research Object
Fine-needle aspiration biopsy samples of thyroid nodules, particularly indeterminate/follicular lesions
Research Subject
Molecular diagnostic markers and assay performance for differentiating malignant from benign thyroid nodules, including sensitivity, specificity, and false-positive/false-negative rates
Publication Details
Publication Date
2011-05-18
Journal
Publisher
ISSN
Cited by
145
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai2
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer2015
A Limited Set of Human MicroRNA Is Deregulated in Follicular Thyroid Carcinoma2006